Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | -3.73% | -7.20% | -27.73% |
31/05 | Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target | MT |
21/05 | Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.73% | 48Cr | |
+18.72% | 12TCr | |
+14.19% | 11TCr | |
-4.93% | 2.42TCr | |
+3.23% | 2.28TCr | |
-10.44% | 1.8TCr | |
-41.74% | 1.64TCr | |
-13.31% | 1.64TCr | |
+2.44% | 1.36TCr | |
+27.89% | 1.17TCr |
- Stock Market
- Equities
- ALLO Stock
- News Allogene Therapeutics, Inc.
- Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating